Molecular classification of solid tumours: towards pathway-driven therapeutics

Abstract

The last decade has witnessed unprecedented developments in the genetic and epigenetic analyses of solid tumours. Transcriptional and DNA copy-number studies have improved our understanding and classification of solid tumours and highlighted the patterns of genomic aberrations associated with outcome. The identification of altered transcriptional and translational silencing by microRNAs and epigenetic modification by methylation in tumours has showed a layer of additional intricacy to the regulation of gene expression in different tumour types. The advent of massive parallel sequencing has allowed whole cancer genomes to be sequenced with extraordinary speed and accuracy providing insight into the bewildering complexity of gene mutations present in solid tumours. Functional genomic studies using RNA interference-screening tools promises to improve the classification of solid tumours by probing the relevance of each gene to tumour phenotype. In this review, we discuss how these studies have contributed to solid tumour classification and why such studies are central to the future of oncology. We suggest that these developments are gradually leading to a change in emphasis of early clinical trials to a therapeutic model guided by the molecular classification of tumours. The investigation of drug efficacy later in development is beginning to rely on patient selection defined by predictive molecular criteria that complement solid tumour classification based on anatomic site.

Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment

“…Over the next few years, enormous amounts of genetic data will likely be generated. Improved tools to analyze cellular pathways and network analyses will become readily available (45)(46)(47)(48)(49)(50)(51). Linking clinical outcome to these genetic data and enforcing open-source data sharing will help to accelerate the development of clinical decision-making algorithms (52,53).…”

Insight into the heterogeneity of breast cancer through next-generation sequencing

“…While most cancer genome studies so far have focused on single patients, this pattern is likely to change as a result of ongoing international collaborations (3) and steep decreases in the cost of sequencing. The hope is that NGS data will shorten the road to personalized medicine, in which treatments and therapies are tailored to target the unique spectrum of mutations that define individual tumors and tumor subpopulations (4)(5)(6)(7)(8). However, this challenge, which has been referred to as "the $1,000 genomes, the $100,000 analysis" problem (9), will only continue to grow.…”

Gene Expression: Protein Interaction Systems Network Modeling Identifies Transformation-Associated Molecules and Pathways in Ovarian Cancer

“…Therapeutic decisions in oncology are based on correlations between tumor characteristics and possibility of disease relapse (1). Limitations of such approaches, however, are now leading to the development of therapies considering individual-specific genetic defects.…”